• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Yunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone Trajectory

    12/16/25 1:32:00 PM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email

    Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today released the following letter to STAAR shareholders in response to the updated reports of Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co., LLC ("Glass Lewis") regarding the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (SIX/NYSE:ALC).

    The text of the letter is as follows:

    December 17, 2025

    Dear Fellow STAAR Shareholders:

    Following our review of the updated reports of the proxy advisory services ISS and Glass Lewis, Yunqi Capital remains opposed to STAAR's proposed merger with Alcon, even at the revised offer price of $30.75.

    We agree with the continued, strong recommendation of Glass Lewis against the merger, as well as with the extensive rationale for Glass Lewis's opposition set forth in its most recently updated report. While we disagree with ISS's recent decision to change its recommendation in favor of the proposed transaction, we underscore that ISS also observed that "it would not necessarily be unreasonable for a shareholder to remain opposed to this transaction."1

    Recent events indicate shareholder value will be maximized if the Company terminates the current agreement and initiates a normal strategic alternatives review in the future.

    When first announcing the conclusion of the go-shop period in a press release, STAAR did not inform shareholders about the appearance, during the go-shop period, of a well-known, credible potential buyer with the capital, industry expertise, buyout experience, and interest to acquire STAAR at a higher price. We are not taking issue with whether STAAR should have disclosed this in its first press release; we are simply highlighting that the third party emerged.

    STAAR then updated shareholders about the appearance of this new third party after questions were raised by other stockholders. When finally acknowledging the appearance of this third party in a second, follow-up press release, STAAR claimed that the potential buyer did not contact STAAR until the beginning of the third week of the go-shop period. STAAR related this claim as if it should be taken to undercut the credibility and meaningfulness of the third party's outreach.

    But STAAR's confirmation of the third-party outreach illustrates the insufficiency of STAAR's go-shop process.

    STAAR had told shareholders in its first press release following the go-shop period, that it had solicited acquisition proposals from a "wide range of potentially interested third parties," yet it missed a well-known and credible party, which also happens to have extensive experience and presence in Asia. STAAR then chose to name this third party in the same follow-up press release, in an unconventional manner. That appears to have chased away the third party, at least for the time being.

    While the Company states that it engaged with 21 third parties, we believe there are far more than 21 potentially interested strategic and financial parties globally. We suspect that this third party and others like it will continue to be in the market in the future.

    The Prospects for the Business Are Strong, in Spite of Leadership Changes that May Come

    We were encouraged to see that ISS expressed well-founded skepticism about STAAR management's pessimistic outlook for the future of the business. ISS stated that "shareholders continue to have a reason to question whether the board's messaging about downside risk from an operational perspective is completely credible."

    We disagree with ISS on its primary basis for its change in recommendation. In reaching its conclusion, ISS focused on a concern that, if shareholders reject the transaction, "shareholders would need to be concerned about next steps for STAA," since "shareholders cannot rely on the incumbent leadership team."

    Our view is that while leadership changes may follow a failed merger vote, the fundamentals of STAAR's business remain firmly intact. In the near term, STAAR shareholders require continuity of operations and stewardship of the business while the Board recalibrates leadership at the senior level. The core drivers of STAAR's value—its proprietary ICL technology, established global distribution infrastructure, and deep penetration in key growth markets—are unchanged. Moreover, the relevant economic data and market indicators underpinning the Company's valuation point to solid and accelerating demand for ICL procedures, reinforcing our view that STAAR's standalone prospects remain strong and continue to improve.

    We also view positively STAAR management's recent comments regarding, in their words, "downward" sales trends in China during the fourth quarter of 2025. Sales trends in the last quarter were already materially better than our expectations. Looking ahead, STAAR China is scheduled to launch the differentiated EVO ICL V5 product line in January 2026. In advance of this launch, we would expect distributors to reduce existing inventories in order to mitigate obsolescence risk and free up capital to support purchases of the new product, which would be priced at an approximately 30-70% premium to the existing line of ICLs, according to our on-the-ground research. This increase in blended average selling price provides an exciting sales driver for 2026 and is under-appreciated by the market.

    This momentum in STAAR's business should not be transferred to Alcon at substantially less than fair value simply because the Company may undertake leadership changes following this failed process. Alcon shareholders should not receive the benefit of this upside in place of STAAR's long-term and loyal shareholders who understand this business and appreciate its value.

    We will continue to vote our shares against the amended merger agreement, and we urge all shareholders to do the same and to continue to have confidence in the standalone prospects for STAAR.

    Sincerely,

    Christopher M. Wang

    Founder and Chief Investment Officer

    Yunqi Capital Limited

    About Yunqi Capital

    Yunqi Capital is a Hong Kong headquartered investment manager with over US$250 million in assets under management. The firm deploys a fundamental long-short equity strategy, with a concentrated portfolio, that is primarily invested in the equity securities of companies with a significant China connection. Yunqi Capital is led by CIO Chris Wang, an experienced portfolio manager with a strong track record of generating attractive returns on capital, controlling portfolio risk and managing investment teams.

    Disclaimers

    THIS IS NOT A SOLICITATION OF AUTHORITY TO VOTE YOUR PROXY. DO NOT SEND US YOUR PROXY CARD OR OTHER VOTING INSTRUCTION FORM. YUNQI CAPITAL IS NOT ASKING FOR YOUR PROXY AND WILL NOT ACCEPT PROXY CARDS IF SENT. YUNQI CAPITAL IS NOT ABLE TO VOTE YOUR PROXY, NOR DOES THIS COMMUNICATION CONTEMPLATE SUCH AN EVENT.

    This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any state to any person. This press release does not recommend the purchase or sale of a security. There is no assurance or guarantee with respect to the prices at which any securities of the Company will trade, and such securities may not trade at prices that may be implied herein. In addition, this press release and the discussions and opinions herein are for general information only, and are not intended to provide investment advice.

    The information contained or referenced herein is for information purposes only in order to provide the views of Yunqi Capital and the matters which Yunqi Capital believes to be of concern to stockholders described herein. The information is not tailored to specific investment objectives, the financial situations, suitability, or particular need of any specific person(s) who may receive the information, and should not be taken as advice in considering the merits of any investment decision. The views expressed herein represent the views and opinions of Yunqi Capital, whose opinions may change at any time and which are based on analyses of Yunqi Capital and its advisors. In addition, the information contained herein is being publicly disclosed without prejudice and shall not be construed to prejudice any of Yunqi Capital's rights, demands, grounds and/or remedies under any contract and/or law.

    This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "in our view", "from our perspective", "intends", "estimates", "plans", "will be", "would" and similar expressions. Although Yunqi Capital believes that the expectations reflected in forward-looking statements contained herein are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties—many of which are difficult to predict and are generally beyond the control of Yunqi Capital or the Company—that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. In addition, the foregoing considerations and any other publicly stated risks and uncertainties should be read in conjunction with the risks and cautionary statements discussed or identified in the Company's public filings with the U.S. Securities and Exchange Commission, including those listed under "Risk Factors" in annual reports on Form 10-K and quarterly reports on Form 10-Q and those related to the pending transaction involving the Company. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Yunqi Capital does not undertake any obligation to update or revise any forward-looking information or statements. Certain information included in this material is based on data obtained from sources considered to be reliable. Any analyses provided to assist the recipient of this material in evaluating the matters described herein may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results. Accordingly, any analyses should not be viewed as factual and should not be relied upon as an accurate prediction of future results. All figures are unaudited estimates and, unless required by law, are subject to revision without notice.

    Funds and investment vehicles (collectively, the "Yunqi Funds") managed or advised by Yunqi Capital currently beneficially own shares of the Company. The Yunqi Funds are in the business of trading (i.e., buying and selling) securities and intend to continue trading in the securities of the Company. You should assume the Yunqi Funds will from time to time sell all or a portion of their holdings of the Company in open market transactions or otherwise, buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares. Consequently, Yunqi Capital's beneficial ownership of shares of, and/or economic interest in, the Company may vary over time depending on various factors, with or without regard to Yunqi Capital's views of the pending transaction or the Company's business, prospects, or valuations (including the market price of the Company shares), including, without limitation, other investment opportunities available to Yunqi Capital, concentration of positions in the portfolios managed by Yunqi Capital, conditions in the securities markets, and general economic and industry conditions. Without limiting the generality of the foregoing, in the event of a change in the Company's share price on or following the date hereof, the Yunqi Funds may buy additional shares or sell all or a portion of their holdings of the Company (including, in each case, by trading in options, puts, calls, swaps, or other derivative instruments). Yunqi Capital also reserves the right to change the opinions expressed herein and its intentions with respect to its investments in the Company, and to take any actions with respect to its investments in the Company as it may deem appropriate, and disclaims any obligation to notify the market or any other party of any such changes or actions, except as required by law.

    ____________________

    1 Permission to use quotes was neither sought nor obtained.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251216088986/en/

    Chris Wang

    cwang@yunqipath.com

    Get the next $ALC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALC
    $STAA

    CompanyDatePrice TargetRatingAnalyst
    Alcon Inc.
    $ALC
    12/11/2025$75.00Buy → Underperform
    BofA Securities
    Alcon Inc.
    $ALC
    8/21/2025Overweight → Neutral
    Analyst
    Alcon Inc.
    $ALC
    5/20/2025Buy → Hold
    Deutsche Bank
    Alcon Inc.
    $ALC
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    STAAR Surgical Company
    $STAA
    4/21/2025$17.00Equal Weight
    Wells Fargo
    Alcon Inc.
    $ALC
    3/28/2025$107.00 → $110.00Buy
    Needham
    Alcon Inc.
    $ALC
    3/25/2025Neutral → Buy
    BofA Securities
    STAAR Surgical Company
    $STAA
    2/12/2025Buy → Hold
    Jefferies
    More analyst ratings

    $ALC
    $STAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Yunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone Trajectory

    Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today released the following letter to STAAR shareholders in response to the updated reports of Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co., LLC ("Glass Lewis") regarding the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (SIX/NYSE:ALC). The text of the letter is as follows: December 17, 2025 Dear Fellow STAAR Shareholders: Following our review of the updated reports of the proxy advisory services ISS and Glass Lewis, Yunqi Capital remains op

    12/16/25 1:32:00 PM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction

    Increased Alcon Merger Price of $30.75 per Share is an Attractive Outcome for STAAR Stockholders STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported that independent industry analysts have recognized the value provided to STAAR stockholders by the Company's amended merger agreement with Alcon (SIX/NYSE:ALC) and the merits of the Alcon transaction. The Alcon merger agreement, as revised on December 9, 2025, provides that STAAR stockholders will receive $30.75 per share in cash if the transaction with Alcon is consummated, representing a 74% premium to STAAR's 90-day Volume

    12/16/25 9:12:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon

    ISS Says It Would Not Be "Unreasonable for a Shareholder to Remain Opposed" to the Deal Broadwood Encourages Shareholders to Follow the Recommendations of Proxy Advisory Firms Glass Lewis and Egan-Jones, Both of Whom Recommend Shareholders Vote "AGAINST" the Proposed Transaction Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today commented on a report published by Institutional Shareholder Services Inc. ("ISS"), an independent proxy advisory firm, which reiterates that firm's significant concerns regarding the proposed acquisition of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) by Alcon Inc. ("Alcon") (NYSE:ALC). ISS stated in its latest report on t

    12/16/25 7:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    SEC Filings

    View All

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    12/16/25 10:17:20 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    12/15/25 7:30:50 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    12/11/25 10:02:03 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Broadwood Partners, L.P. bought $41,060,317 worth of shares (1,500,000 units at $27.37) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    11/21/25 9:55:23 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $2,866,428 worth of shares (187,227 units at $15.31) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/10/25 7:00:22 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $13,627,504 worth of shares (845,220 units at $16.12) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/7/25 8:28:12 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alcon downgraded by BofA Securities with a new price target

    BofA Securities downgraded Alcon from Buy to Underperform and set a new price target of $75.00

    12/11/25 8:51:36 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon downgraded by Analyst

    Analyst downgraded Alcon from Overweight to Neutral

    8/21/25 8:12:09 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon downgraded by Deutsche Bank

    Deutsche Bank downgraded Alcon from Buy to Hold

    5/20/25 8:02:28 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Sisitsky Nathaniel covered exercise/tax liability with 2,616 shares, decreasing direct ownership by 10% to 22,812 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    12/12/25 8:07:52 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $41,060,317 worth of shares (1,500,000 units at $27.37) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    11/21/25 9:55:23 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Director Jiang Wei converted options into 20,967 shares, increasing direct ownership by 86% to 45,477 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    11/14/25 6:00:23 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by STAAR Surgical Company

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    9/6/24 9:51:09 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    2/13/24 5:14:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by Alcon Inc.

    SC 13G - ALCON INC (0001167379) (Subject)

    2/13/24 3:47:46 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    $STAA
    Leadership Updates

    Live Leadership Updates

    View All

    $ALC
    $STAA
    Financials

    Live finance-specific insights

    View All

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Announces Appointment of Deborah Andrews as Chief Financial Officer, Forms Capital Stewardship Committee of the Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Ms. Andrews has served as Interim CFO since March 2025, and she previously served as STAAR's CFO from 2007-2013 and 2017-2020. "Deborah has blended seamlessly with the leadership team, and we quickly realized that her deep knowledge of STAAR and her skills, abilities, and approach made her the perfect choice to be STAAR's next CFO," said the Company's CEO and Board member, Stephen Farrell. "In the last few months, Deborah has

    6/25/25 9:28:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Announces Leadership Transition

    Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to

    2/26/25 4:45:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds

    Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant c

    11/11/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    STAAR Surgical Reports Third Quarter 2025 Results

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended September 26, 2025. Third Quarter 2025 Financial Overview Net sales of $94.7 million up 6.9% Y/Y Net sales included $25.9 million related to the previously disclosed December 2024 ICL shipment that was subject to extended payment terms, and which was paid in full during the third quarter 2025 pursuant to such payment terms (the "December China Shipment") Net sales excluding China of $38.9 million up 7.7% Y/Y Gross margin at 82.2% vs. 77.3% year ago due to the timing of the reco

    11/5/25 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical

    Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month

    8/19/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care